Status:

COMPLETED

A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

Lead Sponsor:

Adherex Technologies, Inc.

Collaborating Sponsors:

US Oncology Research

Conditions:

Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Signed written informed consent
  • Male and female patients \> or = 18 years of age with a solid tumor(s) that is locally advanced or metastatic for which single agent carboplatin, or docetaxel or capecitabine would be appropriate
  • Measurable disease
  • Immunohistochemical evidence of N-cadherin expression in tumor tissue
  • Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and ECG
  • Exclusion criteria:
  • Receipt of ADH-1 prior to this clinical study
  • Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before study entry
  • History of spinal cord compression, or history of primary brain tumor(s) or brain metastases (known or suspected) unless any lesions have completely resolved following appropriate treatment and there has been no recurrence for at least 6 months
  • History of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry
  • Stroke, major surgery, or other major tissue injury within 4 weeks before study entry
  • Uncontrolled congestive heart failure, coronary artery disease, or life threatening arrhythmias; myocardial infarction within 12 months; significant electrocardiogram (ECG) abnormalities, or known hypercoagulable states

Exclusion

    Key Trial Info

    Start Date :

    November 1 2006

    Trial Type :

    INTERVENTIONAL

    End Date :

    November 1 2009

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00390676

    Start Date

    November 1 2006

    End Date

    November 1 2009

    Last Update

    December 28 2010

    Active Locations (10)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (10 locations)

    1

    Rocky Mountain Cancer Centers

    Denver, Colorado, United States, 80218

    2

    Cancer Centers of Florida

    Ocoee, Florida, United States, 34761

    3

    Central Indiana Cancer Centers

    Indianapolis, Indiana, United States, 46219

    4

    New York Oncology Hematology P.C.

    Albany, New York, United States, 12208